Balancen mellem fordele/ risici for bosentan er ikke undersøgt hos patienter med WHO klasse I funktionsstatus ved pulmonal arteriel hypertension.
The benefit/risk balance of bosentan has not been established in patients with WHO class I functional status of pulmonary arterial hypertension.